
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
OncLive® On Air
00:00
Epcot-Nhl1: A Comprehensive Cancer Treatment
An overall response rate of 63%, which is pretty good, but obviously that's not necessarily the biggest indicator of response in diffuse large B-SIL lymphoma. For patients who get a complete remission, it does appear that those patients are having a durable response. The drug is given up at a step up dose in fashion to reduce some of the side effects that we talked about, such as CRS and ICANN's.
Play episode from 04:30
Transcript


